Study of Safety and PK of AZD0543 in Healthy Adults

Exclusion Criteria

• - Hypersensitivity to IMP/components
• - Severe adverse reaction/hypersensitivity to other mAbs
• - Acute fever/illness/infection within 3 days of planned dosing
• - Clinically important illness/procedure/trauma within 4 weeks of IMP administration
• - Active infection with Hepatitis B/C
• - Clinically significant bleeding disorders​
• - Known/suspected immune deficiency/suppression
• - Receipt of blood products/immunoglobulins or immunosuppressive therapies within 6 months prior to screening (immunosuppressive medications/therapies include glucocorticoids exceeding 2 weeks of prednisone (or equivalent) 20mg daily or every other day)
• - Malignancy within previous 5 years; except treated non-melanoma skin cancers and locally treated cervical cancer​
• - Receipt of any licensed/investigational hMPV vaccine, other therapies and procedures as applicable; participation in other clinical studies
• - Screening Abnormalities: clinically significant ECG, positive drug panel, Hgb/platelets/WBC outside of reference; all SCr/AST/ALT > 1.5X ULN ​
• - Women who are pregnant, lactating, or of childbearing potential and not using a highly effective birth control method